An analysis from the EXAMINE trial investigated an extended panel of biomarkers, including hs-cTnI, as predictors of HF after recent ACS in 5380 patients with type 2 diabetes mellitus who were followed for 18 months. The gene discussed is TNNI3; the disease is type 2 diabetes mellitus.